摘要
目的探究多索茶碱联合可必特对支气管哮喘急性发作患者炎症因子及喘息症状缓解的影响。方法采用随机数字表法将2015年4月至2016年4月于本院诊治的86例支气管哮喘急性发作患者分为对照组与观察组。所有患者均给予常规治疗；同时，对照组给予氨茶碱和沙丁胺醇治疗，观察组给予多索茶碱和可必特治疗。通过比较两组炎症因子白细胞介素-4（IL-4）、白细胞介素-12（IL-12）和免疫球蛋白E（IgE）的浓度变化、喘息缓解时间及临床疗效来评估多索茶碱联合可必特治疗支气管哮喘急性发作患者的效果。结果治疗后，观察组IL-12（60．28±10．73）μg／L，总有效率93．02％，显著高于对照组【（45．33±10．68）μg／L、74．42％】，IL-4（62．37±17．82）ng／L，IgE（113．42±18．97）μg/L及喘息缓解时间（3．12±0．74）d，显著低于对照组[（83．47±15．63）ng／L、（143．57±17．69）μg/L、（3．92±0．62）d]（P〈0．05）。结论多索茶碱联合可必特治疗支气管哮喘急性发作患者可有效改善其机体炎症因子水平，缩短喘息症状缓解时间，进而提高临床疗效。
Objective To explore the effect of doxofylline and combivent on inflammatory factors and the relief of wheezing symptoms in patients with acute attack of bronchial asthma. Methods 86 patients with acute attack of bronchial asthma treated at our hospital from April, 2015 to April, 2016 were divided into a control group and an observation group by the random number table method. All the patients were routinely treated. Meanwhile, the control group were treated with aminophylline and salbutamol and the observation group doxofylline and combivent. The changes of the concentrations of inflammatory cytokines, interleukin -4 （IL- 4）, interleukin -12 （IL-12）, and immunoglobulin E （IgE）, asthma remission time, and clinical curative effect were compared between these two groups to evaluate the effect of doxofylline and combivent on patients with acute attack of bronchial asthma. Results After the treatment, the IL-12 level and the total effective rate in the observation group [（60.28±10.73） μg/L, 93.02%] were significantly higher than those in the control group [（45.33±10.68）μg/L, 74.42%], while IL-4, IgE, and asthma remission time [（62.37±17.82） ng/L, （113.42±18.97） μg/L, （3.12±0.74） d] in the observation group were significantly lower than those in the control group [（83.47±15.63） ng/L, （143.57±17.69） gg/L, （3.92±0.62） d] （P 〈 0.05）. Conclusions Doxofylline combined with combivent in the treatment of patients with acute attack of bronchial asthma can effectively improve the levels of inflammatory factors, shorten the relief time of wheezing s,/mptoms, and imlrove clinical curative effect.
出处
《国际医药卫生导报》
2016年第24期3804-3806,共3页
International Medicine and Health Guidance News
